Proenkephalin Improves Cardio-Renal Risk Prediction in Acute Coronary Syndromes: The KID-ACS Score

Heart, Artery and Coronary Diseases

Sex-specific Prediction of Cardiogenic Shock After Acute Coronary Syndromes: The SEX-SHOCK Score

Eur Heart J

Wang Y, Zeller M, Auffret V, Georgiopoulos G, Räber L, Roffi M, Templin C, Muller O, Liberale L, Ministrini S, Stamatelopoulos K, Stellos K, Camici GG, Montecucco F, Rickli H, Maza M, Radovanovic D, Cottin Y, Chague F, Niederseer D, Lüscher TF, Kraler S

doi: 10.1093/eurheartj/ehae593

Heart, Artery and Coronary Diseases

Body temperature, systemic inflammation and risk of adverse events in patients with acute coronary syndromes

Eur J Clin Invest

van der Stouwe JG, Godly K, Kraler S, Godly J, Matter CM, Wenzl FA, von Eckardstein A, Räber L, Mach F, Obeid S, Templin C, Lüscher TF, Niederseer D, SPUM‐ACS investigators

doi: 10.1111/eci.14314

Heart, Artery and Coronary DiseasesTherapy and Intervention

Remote Acute Assessment of Cardiac Patients Post-Acute Coronary Syndrome (TELE-ACS): A Randomized Controlled Trial

J Am Coll Cardiol

Alshahrani NS, Hartley A, Howard J, Hajhosseiny R, Khawaja S, Seligman H, Akbari T, Alharbi BA, Bassett P, Al-Lamee R, Francis D, Kaura A, Kelshiker MA, Peters NS, Khamis R

doi: 10.1016/j.jacc.2024.03.398

Heart, Artery and Coronary Diseases

Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS)

Am Heart J

Gibson CM, Bahit MC, Mehran R, Mehta SR, Lamee RA, Goto S, Weitz JI, Horrow J, Barnathan ES, Harrington RA, Mahaffey KW, Lam CSP, Pieper KS, Johnston SC, Hankey GJ, Plotnikov AN, Li D, Deng H, Steg PG, Librexia ACS Committees and Investigators.

doi: 10.1016/j.ahj.2025.02.011

Heart, Artery and Coronary Diseases

Sex differences in survival following acute coronary syndrome with and without standard modifiable risk factors

Clin Res Cardiol

Anand VV, Koh J, Teo T, Chin YH, Mahesh R, Chan MY, Figtree GA, Chew NWS

doi: 10.1007/s00392-024-02563-7

Heart, Artery and Coronary Diseases

Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study

Eur Heart J Cardiovasc Pharmacother

Bruno F, Wenzl FA, De Filippo O, Kraler S, Giacobbe F, Roffi M, Muller O, Räber L, Templin C, Maria De Ferrari G, D'Ascenzo F, Lüscher TF

doi: 10.1093/ehjcvp/pvae024

Heart, Artery and Coronary DiseasesFurther Publications

Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial

JAMA Cardiol

Li Y, Li J, Wang B, Jing Q, Zeng Y, Hou A, Wang Z, Liu A, Zhang J, Zhang Y, Zhang P, Jiang D, Liu B, Fan J, Zhang J, Li L, Su G, Yang M, Jiang W, Qu P, Zeng H, Li L, Qiu M, Ru L, Chen S, Zhou Y, Qiao S, Stone GW, Angiolillo DJ, Han Y, OPT-BIRISK Investigators

doi: 10.1001/jamacardio.2024.0534

Heart, Artery and Coronary Diseases

Percutaneous coronary intervention plus medical therapy versus medical therapy alone in chronic coronary syndrome: a propensity score-matched analysis from the Swedish Coronary Angiography and Angioplasty Registry

Heart

von Koch S, Koul S, Grimfjärd P, Andersson J, Jernberg T, Omerovic E, Fröbert O, Erlinge D, A Mohammad M

doi: 10.1136/heartjnl-2024-324307

Heart, Artery and Coronary Diseases

European and US Guideline-Based Statin Eligibility, Genetically Predicted Coronary Artery Disease, and the Risk of Major Coronary Events

J Am Heart Assoc

Park H, Kim D, You SC, Jang E, Yu HT, Kim TH, Kim DM, Sung JH, Pak HN, Lee MH, Yang PS, Joung B

doi: 10.1161/JAHA.123.032831

Related content

Sex-specific Prediction of Cardiogenic Shock After Acute Coronary Syndromes: The SEX-SHOCK Score

Body temperature, systemic inflammation and risk of adverse events in patients with acute coronary syndromes

Remote Acute Assessment of Cardiac Patients Post-Acute Coronary Syndrome (TELE-ACS): A Randomized Controlled Trial

Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS)

Sex differences in survival following acute coronary syndrome with and without standard modifiable risk factors

Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study

Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial

Percutaneous coronary intervention plus medical therapy versus medical therapy alone in chronic coronary syndrome: a propensity score-matched analysis from the Swedish Coronary Angiography and Angioplasty Registry

European and US Guideline-Based Statin Eligibility, Genetically Predicted Coronary Artery Disease, and the Risk of Major Coronary Events